The whole is greater than the sum of its parts – the power of unifying perspectives in Secondary Immunodeficiency (SID)

Takeda is delighted to be here with you at the ESID 2021 virtual meeting.

In this short video, Julie Kim, President of Plasma Derived Therapies and Alan Walshe, Global Head of Product and Launch Strategy for PDT provide a teaser of Takeda’s activities this year, as well as discussing Takeda’s ongoing commitment to patients living with secondary immunodeficiencies (SID).

Please join us at our virtual symposium on Tuesday 28 September at 13:00 CEST | 12:00 BST | 14:00 EEST.

Takeda is committed to the ongoing development of Immunoglobulin therapies that could help protect patients with SID from infections and to raise awareness of the impact of this condition.

The advent of new molecules and targeted therapies in hemato-oncology has brought remarkable benefits in the treatment of a range of conditions,1–3 yet can come with side effects, including the development of SID with resultant recurrent or severe infections.

Even though ESID is virtual this year, we are here throughout the meeting, so please come and connect with us in the Takeda lounge where you will find a link, which allows you to ask all your questions.


Julie Kim

Julie Kim is the President of the Plasma-Derived Therapies Business Unit for Takeda Pharmaceutical Company Ltd. Ms. Kim joined Takeda in 2019 through the acquisition of Shire, where she held multiple diverse roles with increasing responsibility through her time at Baxter/Baxalta/Shire. These roles included Global Franchise Head in a number of therapy areas, international market access, country and regional general management, marketing and emerging market development.


Alan Walshe

Alan Walshe is the Global Head of Product and Launch Strategy for Plasma-Derived Therapies at Takeda Pharmaceutical Company Ltd. Mr. Walshe joined Takeda in 2019. Prior to this he was the Senior Director of UK Haematology Franchise Head for Shire. His time at Baxalta/Baxter/Shire before starting at Takeda included various roles such as Global Marketing Director for Immunology, Group Product Manager for Immunology, Hemophilia, Vaccines and many more.


  1. Valent P, et al. Hemasphere 2021;5:e536.
  2. Bashraheel SS, et al. Biomed Pharmacother 2020;125:110009.
  3. Delmonte OM & Notarangelo LD. Med Princ Pract 2020;29:101–112.

This webpage and the video within it have been initiated, produced and funded by Takeda.

The Takeda symposium is for non-US and non-UK healthcare professionals only.

The Takeda symposium is not included in main meeting CME/CPD credit.

To send a comment or question to Takeda Pharmaceutical Company Limited, please contact us here

Copyright 2021 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.

 September 2021